James A. Knost - Concepedia

Author

James A. Knost

Illinois CancerCare

Also Known As

J A Knost, J Knost, J. A. Knost, J. Knost, J.A. Knost, JAMES A. KNOST, JAMES KNOST, James A. Knost, James Knost

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Illinois CancerCare Mayo Clinic Iowa Oncology Research Association University of Chicago OSF Saint Francis Medical Center

About

James A. Knost is an author at Illinois CancerCare specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	997
2	Health Sciences	4	4	356
3	Education	1	1	11
4	Law	1	1	11
5	Allergy	1	1	82

James A. Knost

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Evaluation of Soy Phytoestrogens for the Treatment of Hot Flashes in Breast Cancer Survivors: A North Central Cancer Treatment Group Trial Susan K. Quella, Charles L. Loprinzi, Debra L. Barton, Journal of Clinical Oncology	2000	375
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. Henry C. Pitot, Donald B. Wender, Matthew J. O’Connell, Journal of Clinical Oncology	1997	257
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling Alexa B. Schrock, Shuyu Dan Li, Garrett M. Frampton, Journal of Thoracic Oncology Somatic VariantTumor HeterogeneityComprehensive Genomic ProfilingMedicinePathology	2017	164
A Multiple-Dose Phase I Trial of Recombinant Leukocyte A Interferon in Cancer Patients Stephen A. Sherwin, James A. Knost, Seymour Fein, JAMA ImmunologyPathologyCancer PatientsBiological ResponseImmunotherapy	1982	150
The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type Leora Witkowski, Catherine Goudie, Pilar Ramos, Gynecologic Oncology Cancer RiskMedicineHypercalcemic TypeSmall Cell CarcinomaPathology	2016	125
Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma Steven R. Alberts, Hani Alkhatib, Michelle R. Mahoney, Cancer	2004	116
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia Halla Nimeiri, Amit M. Oza, Robert J. Morgan, Gynecologic Oncology Tumoral PathologyMedicineGynecologyAdvanced Uterine Carcinoma/carcinosarcomaPhase Ii Study	2010	90
Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking R. Douglas Hurt, James E. Krook, Ivana T. Croghan, Journal of Clinical Oncology	2003	87
Determination of the optimal human cell lines for development of human hybridomas. Paul G. Abrams, James A. Knost, G. Clarke, The Journal of Immunology HistocompatibilityImmunoglobulin SecretionImmunologyHuman HybridomasImmunophenotyping	1983	82
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer Muhammad Wasif Saif, James A. Knost, E. Gabriela Chiorean, Cancer Chemotherapy and Pharmacology MedicineImmunologyColorectal CancerPathologyImmune Checkpoint Inhibitor	2016	73

Page 1